Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.
Treatment of children with cancer requires access to and reimbursement of effective drugs. Children with haemato-oncological diseases are often treated according to established treatment recommendations or in the framework of late-phase clinical trials. These often involve the use of drugs authorised for adults but which, however, have been used for many years in paediatrics with no perspective of authorisation in children. In Belgium, medicines are predominantly reimbursed based on their authorised indication. As a consequence, many drugs used in paediatric haemato-oncology are used off-label... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
Springer Verlag
|
Schlagwörter: | Adult / Belgium / Child / Humans / Neoplasms / Off-Label Use / Pediatrics / Pharmaceutical Preparations / Haematology / Oncology / Paediatrics / Reimbursement |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26530083 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/260908 |